BioCentury | Nov 20, 2020

China in-licensing play LianBio follows $310M crossover round with broad Pfizer deal

Pfizer’s deal with LianBio will provide the Perceptive-backed, cross-border start-up with a commercial infrastructure in China, while giving the pharma a drug hunter and development partner led by veteran China biotech executives Bing Li and Debra...
BioCentury | Oct 29, 2020

Perceptive-backed in-licensing play LianBio to cast a wide net with $310M crossover round

A $310 million crossover round will enable Chinese in-licensing play LianBio to “cast a wide net” as it looks to build a broad portfolio, Perceptive’s Adam Stone told BioCentury. Perceptive Advisors seeded,...
BioCentury | Oct 27, 2020
Product Development

Mirati impresses with KRAS inhibitor response rates, potential biomarker

Mirati’s shares rose to an all-time high on Monday after the company dropped the latest response rate data in the closely-watched KRAS inhibitor race, but it’s still too early to tell how adagrasib (MRTX849) will...
BioCentury | Oct 2, 2020

C4 is latest preclinical protein degradation IPO with big aftermarket gain

Public investors again showed their appetite for protein degradation companies Friday, as C4’s upsized IPO was the largest and best-received of three new NASDAQ listings.  Shares of C4 Therapeutics Inc. (NASDAQ:CCCC), a preclinical company based...
BioCentury | Sep 17, 2020

Mirati and Boehringer partner to test KRAS-KRAS combo

Mirati and Boehringer have teamed up to test the hypothesis that two KRAS inhibitors are better than one after preclinical data suggested blocking the oncogene in different ways may produce complementary effects. The companies will...
BioCentury | Aug 11, 2020
Emerging Company Profile

Through LianBio, Perceptive forms bridge for Western pipeline into Asia

Led by Bing Li and Debra Yu, Perceptive’s LianBio has launched with the goal of speeding the entrance of new medicines into Asian markets, leading with a registration-ready cardiomyopathy candidate from MyoKardia and a Phase...
BioCentury | Jul 16, 2020

Relay’s IPO among the year’s largest for a biotech as others wait in wings

In a year when most new biotech listings have surpassed expectations, Relay’s upsized $400 million IPO is the second-largest yet for a therapeutics developer in 2020. The clinical developer of precision oncology therapies posted a...
BioCentury | Jun 2, 2020
Product Development

Sanofi makes case for why its first cancer drug in a decade can take on Darzalex

Carving a space in the crowded multiple myeloma market for recently approved Sarclisa is one of the four pillars of Sanofi’s strategy for re-entering oncology, and the company believes new data strengthen the case for...
BioCentury | Apr 25, 2020
Targets & Mechanisms

Trends to surf for at AACR 2020

While the abstracts for this year’s virtual AACR meeting won’t be available until Monday -- and most data won’t be presented until June -- key session titles, combined with an analysis of recent trends in...
BioCentury | Mar 7, 2020
Product Development

If NoNO’s stroke trial strategy pays off, it could bring the first new therapy in a generation

Building on decades of work on a new mechanism, NoNO Inc. is laying the groundwork for an FDA approval in stroke, a notoriously difficult indication that hasn’t seen a new therapy in almost 25 years....
Items per page:
1 - 10 of 410